JonesResearch Reiterates Buy on AbCellera Biologics (ABCL)

On April 22, 2026, JonesResearch highlighted AbCellera Biologics Inc. (NASDAQ:ABCL), noting that if its ABCL635 campaigner demonstrates cleanable information with nary hepatic signals and achieves people engagement comparable to Veohah and Lynkuet, the therapy could beryllium “very competitive.” The steadfast has reiterated its Buy standing and $11 terms people connected AbCellera Biologics Inc. (NASDAQ:ABCL) up of a Phase 1 update expected connected May 11, 2026.

Just earlier successful the period of April, JonesResearch expert Debanjana Chatterjee initiated sum of AbCellera Biologics Inc. (NASDAQ:ABCL) with a Buy standing and $11 terms people connected the shares. The steadfast has said that AbCellera Biologics Inc. (NASDAQ:ABCL)’s antibody find level has precocious 19 molecules into objective improvement crossed some interior and partnered programs spanning aggregate therapeutic areas, with its capabilities “best illustrated” done its collaboration with Eli Lilly.

AbCellera Biologics Inc. (NASDAQ:ABCL) develops antibody-based therapies targeting diseases with unmet aesculapian needs.

While we admit the imaginable of ABCL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.